GALT · NASDAQ
Galectin Therapeutics (GALT) Stock Price & Fundamentals
Galectin Therapeutics (GALT) closed at $473.98 on Oct 9, 2026, up 0.30% from the previous close of $472.56.
Share price, past year
1Y −3.60%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $473.98 |
| Sep 30, 2026 | $473.70 |
| Aug 31, 2026 | $470.09 |
| Jul 31, 2026 | $490.55 |
| Jun 30, 2026 | $466.82 |
| May 29, 2026 | $484.46 |
| Apr 30, 2026 | $483.83 |
| Mar 31, 2026 | $470.29 |
| Feb 27, 2026 | $489.85 |
| Jan 30, 2026 | $525.19 |
| Dec 31, 2025 | $547.40 |
| Nov 28, 2025 | $536.88 |
| Oct 31, 2025 | $506.83 |
Key statistics
- Market cap
- $31.43B
- EPS (TTM)
- −$0.43
- Net income (TTM)
- −$27.84M
- Shares outstanding
- 66.3M
- 52-week range
- $448.64 – $570.18
Galectin Therapeutics's market cap is $31.43B, based on a share price of $473.98 and 66.3M shares outstanding as of Jun 30, 2026.
Financials
Galectin Therapeutics's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Galectin Therapeutics reported a net loss of $30.84M in fiscal 2025.
Company profile
- Name
- Galectin Therapeutics Inc.
- Ticker
- GALT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071
- Incorporated in
- NV
- Fiscal year ends
- December
- SEC CIK
- 0001133416
Recent SEC filings
- Aug 14, 2026
- Aug 14, 2026
- Aug 4, 2026
- Jun 23, 2026
- May 15, 2026
- May 15, 2026
- Mar 31, 2026
- Mar 31, 2026
Frequently asked questions
What is Galectin Therapeutics's stock price?
Galectin Therapeutics (GALT) closed at $473.98 on Oct 9, 2026, up 0.30% from the previous close of $472.56.
What is Galectin Therapeutics's market cap?
Galectin Therapeutics's market cap is $31.43B, based on a share price of $473.98 and 66.3M shares outstanding as of Jun 30, 2026.
Does Galectin Therapeutics pay a dividend?
Galectin Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Galectin Therapeutics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures